Search Results

The Neonatal Biotinidase kit is intended for the semiquantitative determination of biotinidase activity in blood specimens dried on filter paper as an aid in screening newborns for biotinidase deficiency.

Biotinidase is found in the blood sample itself. Filter paper disks from newborn dried blood spot samples, calibrators and controls are punched into the wells of a microplate. When biotin substrate reagent containing biotin 6-aminoquinoline (6-AQ) is added to a well containing a punched dried blood spot, the reagent extracts and reconstitutes the proteins and enzymes in the spot. The biotinidase enzyme in the sample cleaves the substrate to biotin and fluorescent 6-AQ The addition of the ethanol stops the reaction and precipitates the proteins to cover the bottom of the well and the extracted spot. The fluorescent product (6-AQ) formed during the reaction is measured with a fluorometer. The biotinidase activity is defined against a calibration curve. The biotinidase activity of the sample is determined by comparing the fluorescence intensity of the sample to a calibration curve.

The Neonatal Biotinidase kit is intended for the semi-quantitative determination of biotinidase activity in blood specimens dried on filter paper as an aid in screening newborns for biotinidase deficiency. The study aimed to demonstrate substantial equivalence to the Astoria-Pacific SPOTCHECK® Biotinidase 50-Hour Reagent Kit (K010844).

1. Table of Acceptance Criteria and Reported Device Performance:

The document describes a method comparison study to establish substantial equivalence rather than explicit acceptance criteria with pre-defined thresholds. However, based on the provided results, the implicit acceptance criteria would involve high positive percent agreement (PPA) and overall percent agreement (OPA) with the predicate device.

2. Sample Size Used for the Test Set and Data Provenance:

• Test Set Sample Size: 1516 samples.
• Data Provenance: The samples included 1516 newborn dried blood spot specimens representing the US population. The study included:
  • 1496 routine screening specimens (prospective, from the US population).
  • 20 retrospective specimens diagnosed positive for biotinidase deficiency (provenance not explicitly stated but implies confirmed cases, likely from a US population or referral lab).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications:

The document does not specify the number or qualifications of experts used to establish the ground truth. It states that 20 retrospective specimens were "diagnosed positive for biotinidase deficiency," implying a clinical diagnosis, but details on who made these diagnoses are not provided. For the routine screening samples, the ground truth is established by the comparison to the predicate device and clinical outcome (diagnosed biotinidase deficiency or not).

4. Adjudication Method for the Test Set:

Not applicable. This study is a method comparison between two assays, not a diagnostic study requiring adjudication against a clinical outcome based on expert review of ambiguous cases. The "ground truth" for the deficient samples appears to be established by prior clinical diagnosis, and routine samples are compared against the predicate as well as clinical diagnosis outcomes.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study:

No, an MRMC comparative effectiveness study was not done. This study is a comparison of two diagnostic assays, not an assessment of human reader performance with or without AI assistance.

6. Standalone (Algorithm Only) Performance Study:

Yes, a standalone study was performed. The device (Neonatal Biotinidase kit) was tested on its own and its results were compared to those from a commercially available predicate device. The performance metrics (PPA, OPA) are based on the direct output of the device.

7. Type of Ground Truth Used:

The ground truth for the 20 positive cases was established by clinical diagnosis ("retrospective specimens diagnosed positive for biotinidase deficiency"). For the routine samples, the "ground truth" for comparison purposes within the study was intrinsically linked to the results of the predicate device and the absence of a biotinidase deficiency diagnosis.

8. Sample Size for the Training Set:

The document does not provide information on a specific training set or its sample size for the Neonatal Biotinidase kit. Kits for in vitro diagnostic (IVD) use typically involve extensive assay development and validation, but specific "training sets" in the machine learning sense are not usually reported in this context. The calibration curve and internal controls are part of the assay's design and standardization.

9. How the Ground Truth for the Training Set Was Established:

As no specific training set in the AI/ML sense is mentioned, information on how its ground truth was established is not provided. The kit's calibration curve is established using six levels of dried blood spots prepared from porcine blood, representing different biotinidase activity levels, which serves as a form of internal reference material.

Ask a specific question about this device